Search
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalIt is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.[L13604] Selpercatinib is also approved by the European Commission. … [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific
Tauroursodeoxycholic acid
go.drugbank.com/drugs/DB08834ApprovedInvestigationalWithdrawn[A249070] It is a taurine conjugate of [ursodeoxycholic acid] [A249065] with comparable therapeutic efficacy and safety,[A249070] but a much higher hydrophilicity. … [A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative.
Xylometazoline
go.drugbank.com/drugs/DB06694ApprovedXylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels. … [A228508] Xylometazoline is available in over-the-counter (OTC) nasal sprays or drops to temporarily relieve nasal congestion due to cold, hay fever or other respiratory allergies.
Products: NASENSPRAY ELAC 1MG/ML OK, OLYNTH 0.05% N O KONSERVIEDifelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665] … [A237620] Options for therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and widely available treatment.
Betaine
go.drugbank.com/drugs/DB06756ApprovedInvestigationalNutraceuticalCurrently, no treatments are available to correct the genetic causes of homocystinuria. … [L43105] Although it is present in many food products, the levels found there are insufficient to treat this condition.
Synonyms: 2-N,N,N-trimethylammonio acetate, N,N,N-TrimethylglycineMixtures: Neo Life Beta Gest TabDifamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalAtopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.
Eculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. … [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigationalTafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal. … [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Mazindol
go.drugbank.com/drugs/DB00579ApprovedMazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects. … It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalIt was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein.